GlassScriptPhysician profile
Hongha Vu-James
NPI 1174798805
$3,687.80
in general payments reported to CMS, 2019-2025
26 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $123 · 2021: $936 · 2022: $570 · 2023: $380 · 2024: $698 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,170.24 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $708.88 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $294.64 | 2019-2024 | |
| Janssen Biotech, INC. | $258.46 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $168.63 | 2019-2024 | |
| Madrigal Pharmaceuticals | $161.61 | 2024-2025 | Resmetirom, Rezdiffra |
| Celgene Corporation | $159.02 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $145.18 | 2019-2025 | Entyvio |
| La Jolla Pharmaceutical Company | $114.59 | 2021 | |
| Lilly USA, LLC | $61.13 | 2025 | Omvoh |
| Echosens North America, INC. | $59.07 | 2023 | Fibroscan |
| Braintree Laboratories, INC. | $50.84 | 2020-2021 | |
| Ardelyx, INC. | $36.72 | 2023-2025 | Ibsrela |
| Shionogi INC | $34.58 | 2019 | |
| Redhill Biopharma INC. | $33.69 | 2022-2023 | Talicia, Movantik, Aemcolo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $31.19 | 2019-2021 | |
| Ethicon US, LLC | $27.26 | 2022 | |
| Daiichi Sankyo INC. | $24.58 | 2019 | |
| Genzyme Corporation | $24.42 | 2022 | |
| Acacia Pharma INC | $20.73 | 2021 | |
| Amgen INC. | $19.99 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $18.45 | 2022 | |
| Baxter Healthcare | $17.49 | 2021 | |
| Avanos Medical | $16.72 | 2020 | |
| Boston Scientific Corporation | $15.18 | 2019 | |
| Allergan, INC. | $14.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongha Vu-James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.